January 06, 2010
saxagliptin
- Brand name in US: Onglyza®
- Class: DPP-4 inhibitor
- For: Type 2 diabetes
- Route of Administration: oral
- Action: inhibits DPP-4 (dipeptidyl peptidase-4), allowing potentiation of the secretion of insulin by beta cells.
- Manufacturer: Bristol-Myers Squibb in collaboration with AstraZenaca
- Status: Approved in the US July 31, 2009. EMEA approval June, 2009; anticipated launch in Germany in the third quarter of 2009.
- Sources: Press release from manufacturer: U.S. Food and Drug Administration Approves ONGLYZA™ (saxagliptin) for the Treatment of Type 2 Diabetes Mellitus in Adults; news story AstraZeneca, Bristol-Myers Prepare for German Onglyza Start
- Other drugs in the same class: Januvia (sitagliptin) (approved in US and Europe); Galvus (vitagliptin) (approved in Europe; undergoing FDA review as of August 2009).
